

**SkyePharma**

28 June 2006

For the attention of Dr Daniel Brasseur
European Medicines Agency
7 Westferry Circus
Canary Wharf
London
E14 4HB
United Kingdom

**Subject: Withdrawal of DepoCyt (cytarabine), 50mg Suspension for Injection -
EMEA/H/C/317/H/0010**

Dear Dr Brasseur,

I would like to inform you that, at this point of time, SkyePharma has taken the decision to withdraw the application for a new indication, in the treatment of solid tumour neoplastic meningitis.

This withdrawal is based on the following reason

- the CHMP considers that the data provided do not allow the committee to conclude on a positive benefit risk balance

This decision has no consequences for patients enrolled in clinical trials or compassionate use programmes.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMEA website.

Yours sincerely,

Chief Scientific Officer
SkyePharma PLC